Valuation : PYC Therapeutics Limited

Market Cap 2.25B 1.61B 1.39B 1.31B 1.19B 2.24B 153B 15.46B 6.01B 77.71B 6.04B 5.91B 258B P/E 2027 *
-26.6x
P/E 2028 * -28x
Enterprise Value 1.65B 1.18B 1.02B 959M 874M 1.64B 112B 11.35B 4.42B 57.08B 4.44B 4.34B 189B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
67.03%
Yield 2027 *
-
Yield 2028 * -
1 day-1.29%
1 week+9.05%
Current month-1.29%
1 month+34.71%
3 months+69.63%
6 months+52.16%
Current year+38.37%
1 week 2.09
Extreme 2.09
2.35
1 month 1.68
Extreme 1.68
2.35
Current year 1.04
Extreme 1.045
2.35
1 year 0.85
Extreme 0.847
2.35
3 years 0.52
Extreme 0.52
2.35
5 years 0.5
Extreme 0.5
2.35
10 years 0.15
Extreme 0.15
2.35
Manager TitleAgeSince
Chief Executive Officer 42 19/08/2020
Director of Finance/CFO 47 07/07/2026
Chief Tech/Sci/R&D Officer - 01/08/2025
Director TitleAgeSince
Director/Board Member 42 30/11/2018
Director/Board Member - 22/09/2025
Chairman 66 18/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
13/08/26 Free

Chief Executive Officer

4,598,662 0.4676%
13/08/26 Free

Chief Executive Officer

10,477,965 1.0654%
13/08/26 Free

Chief Executive Officer

7,706,503 0.7836%
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%+9.05%+78.91%+294.83% 1.63B
+0.21%-1.70%+1.90%+18.18% 49.81B
+2.09%-0.81%+452.73%+517.81% 44.06B
-1.09%-0.73%+35.40%+16.04% 42.99B
-0.26%-3.58%+17.19%+72.80% 40.88B
-0.48%-3.09%+17.78%+49.80% 33.11B
-1.81%-5.94%+22.65%+115.79% 16.58B
-1.06%+3.29% - - 17.27B
-1.35%-2.32%+10.40%+25.90% 14.63B
-2.05%-5.44%+72.89%+36.51% 13.76B
Average -0.94%-0.43%+78.87%+127.52% 27.47B
Weighted average by Cap. -0.62%-1.72%+95.22%+125.53%

Financials

2027 *2028 *
Net sales - -
Net income -81.84M -58.48M -50.43M -47.45M -43.23M -81.25M -5.55B -562M -218M -2.82B -220M -215M -9.37B -82.2M -58.74M -50.65M -47.66M -43.42M -81.61M -5.58B -564M -219M -2.84B -220M -216M -9.41B
Net Debt -598M -427M -369M -347M -316M -594M -40.57B -4.1B -1.6B -20.64B -1.6B -1.57B -68.46B -531M -380M -327M -308M -281M -528M -36.05B -3.65B -1.42B -18.34B -1.43B -1.39B -60.83B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
01/09/26 A$2.290 -1.29% 7,476,947
31/08/26 A$2.320 +3.11% 8,641,108
28/08/26 A$2.250 -0.44% 1,548,143
27/08/26 A$2.260 +4.15% 2,391,608
26/08/26 A$2.170 +4.33% 1,360,907
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.290AUD
Average target price
3.798AUD
Spread / Average Target
+65.85%

Quarterly revenue - Rate of surprise